Cargando…

How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey

Detalles Bibliográficos
Autores principales:	Palandri, Francesca, Piciocchi, Alfonso, De Stefano, Valerio, Breccia, Massimo, Finazzi, Guido, Iurlo, Alessandra, Fazi, Paola, Soddu, Stefano, Martino, Bruno, Siragusa, Sergio, Albano, Francesco, Passamonti, Francesco, Vignetti, Marco, Vannucchi, Alessandro M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333222/ https://www.ncbi.nlm.nih.gov/pubmed/32620840 http://dx.doi.org/10.1038/s41375-020-0953-3

Ejemplares similares

COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey
por: Breccia, Massimo, et al.
Publicado: (2020)

Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine
por: Breccia, M., et al.
Publicado: (2022)

Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios
por: Palandri, Francesca, et al.
Publicado: (2021)

Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey
por: Breccia, Massimo, et al.
Publicado: (2023)

P495: UNLOCKING THE POTENTIAL OF SYNTHETIC PATIENTS FOR ACCELERATING CLINICAL TRIALS: RESULTS OF THE FIRST GIMEMA EXPERIENCE
por: Piciocchi, Alfonso, et al.
Publicado: (2023)

The GIMEMA-ALLIANCE Digital Health Platform for Patients With Hematologic Malignancies in the COVID-19 Pandemic and Postpandemic Era: Protocol for a Multicenter, Prospective, Observational Study
por: Efficace, Fabio, et al.
Publicado: (2021)

Blastic plasmocitoid dendritic cell neoplasm with leukemic spread: a GIMEMA survey
por: Valentini, Caterina Giovanna, et al.
Publicado: (2021)

Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms
por: Mora, Barbara, et al.
Publicado: (2022)

A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol
por: Chiaretti, Sabina, et al.
Publicado: (2021)

NK Cells in Myeloproliferative Neoplasms (MPN)
por: Naismith, Erin, et al.
Publicado: (2021)

Renal biopsy cases in myeloproliferative neoplasms (MPN)
por: Fujita, Kumi, et al.
Publicado: (2013)

Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol
por: Messina, Monica, et al.
Publicado: (2022)

Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
por: Barbui, Tiziano, et al.
Publicado: (2022)

Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives
por: Baumeister, Julian, et al.
Publicado: (2021)

Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification
por: Hebeda, Konnie M., et al.
Publicado: (2009)

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
por: Kaifie, A., et al.
Publicado: (2016)

Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature
por: Yadav, Ruchi, et al.
Publicado: (2023)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

PB2058: IMPACT OF COMORBIDITIES AND RESPONSE TO TREATMENT ON THE MPN SAF ASSESSMENT OF PHILADELPHIA CHROMOSOME NEGATIVE MYELOPROLIFERATIVE SYNDROMES.
por: Mohamed, B., et al.
Publicado: (2022)

Thromboinflammation in Myeloproliferative Neoplasms (MPN)—A Puzzle Still to Be Solved
por: Bhuria, Vikas, et al.
Publicado: (2022)

Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID‐19: The GIMEMA EMATO‐0321 study
por: Marasco, Vincenzo, et al.
Publicado: (2022)

Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic
por: Barbui, Tiziano, et al.
Publicado: (2021)

ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
por: Buccisano, Francesco, et al.
Publicado: (2022)

P984: MUTATIONAL PATTERNS IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
por: Casetti, I. C., et al.
Publicado: (2022)

Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms
por: Barbui, Tiziano, et al.
Publicado: (2018)

P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA
por: Venditti, Adriano, et al.
Publicado: (2023)

Philadelphia-negative chronic myeloproliferative neoplasms
por: Bittencourt, Rosane Isabel, et al.
Publicado: (2012)

IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis
por: Cumbo, Cosimo, et al.
Publicado: (2021)

P523: THE COMPARISON OF VFLAI, FLAI AND 3 + 7 REGIMENS BY MULTILEVEL PROPENSITY SCORE WEIGHTING HIGHLIGHTS THE BENEFIT OF THE ADDITION OF VENETOCLAX IN NO LOW-RISK AML TREATED IN GIMEMA TRIALS AND REAL WORLD
por: Piciocchi, Alfonso, et al.
Publicado: (2023)

Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN
por: Kricheldorf, Kim, et al.
Publicado: (2021)

Molecular biology of Philadelphia-negative myeloproliferative neoplasms
por: Campregher, Paulo Vidal, et al.
Publicado: (2012)

Inflammatory picture of Philadelphia-negative myeloproliferative neoplasms()
por: Pagnano, Katia Borgia Barbosa
Publicado: (2018)

Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper
por: Barbui, Tiziano, et al.
Publicado: (2019)

Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms
por: De Stefano, Valerio, et al.
Publicado: (2018)

A case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) successfully treated with lenalidomide
por: Islam, Anwarul
Publicado: (2015)

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913
por: Chiaretti, Sabina, et al.
Publicado: (2020)

American Society of Hematology 2020 Podcast Collection: MPN
por: Breccia, Massimo
Publicado: (2021)

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Survival Patterns in United States (US) Medicare Enrollees with Non-CML Myeloproliferative Neoplasms (MPN)
por: Price, Gregory L., et al.
Publicado: (2014)

Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells
por: Fiskus, Warren, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_erg361dg8pe0thsbvd9t1kgg1l